S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ARDX

Ardelyx (ARDX) Stock Price, News & Analysis

$7.41
-0.01 (-0.13%)
(As of 03/27/2024 ET)
Today's Range
$7.31
$7.65
50-Day Range
$7.41
$9.74
52-Week Range
$3.16
$10.13
Volume
4.52 million shs
Average Volume
6.32 million shs
Market Capitalization
$1.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.36

Ardelyx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
66.8% Upside
$12.36 Price Target
Short Interest
Bearish
15.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
0.40mentions of Ardelyx in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to $0.08 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

130th out of 939 stocks

Pharmaceutical Preparations Industry

52nd out of 422 stocks

ARDX stock logo

About Ardelyx Stock (NASDAQ:ARDX)

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Stock Price History

ARDX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
ARDX Apr 2024 7.500 put
ARDX Apr 2024 10.000 call
Ardelyx Inc
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Short Interest in Ardelyx, Inc. (NASDAQ:ARDX) Expands By 11.8%
Guru Fundamental Report for ARDX
ARDX Mar 2024 11.000 call
ARDX Mar 2024 8.000 put
ARDX Mar 2024 8.000 call
ARDX Mar 2024 8.500 call
ARDX Mar 2024 10.000 put
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Ardelyx, Inc. Reports Employment Inducement Grants
ARDX Mar 2024 12.000 call
ARDX Mar 2024 7.500 put
ARDX Mar 2024 7.500 call
Stocks on the Launchpad: The Next 3 Market Sensations
Q4 2023 Ardelyx Inc Earnings Call
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/27/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARDX
Employees
267
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$12.36
High Stock Price Target
$15.00
Low Stock Price Target
$8.50
Potential Upside/Downside
+66.8%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-66,070,000.00
Pretax Margin
-52.65%

Debt

Sales & Book Value

Annual Sales
$124.46 million
Book Value
$0.72 per share

Miscellaneous

Free Float
219,888,000
Market Cap
$1.72 billion
Optionable
Optionable
Beta
0.88

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

ARDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price target for 2024?

7 equities research analysts have issued 12-month price targets for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they expect the company's stock price to reach $12.36 in the next year. This suggests a possible upside of 66.8% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2024?

Ardelyx's stock was trading at $6.20 at the start of the year. Since then, ARDX shares have increased by 19.5% and is now trading at $7.41.
View the best growth stocks for 2024 here
.

Are investors shorting Ardelyx?

Ardelyx saw a increase in short interest in March. As of March 15th, there was short interest totaling 36,310,000 shares, an increase of 8.0% from the February 29th total of 33,610,000 shares. Based on an average trading volume of 6,230,000 shares, the short-interest ratio is currently 5.8 days.
View Ardelyx's Short Interest
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. The biopharmaceutical company earned $34.36 million during the quarter, compared to analyst estimates of $34.26 million. Ardelyx had a negative net margin of 53.08% and a negative trailing twelve-month return on equity of 43.57%. Ardelyx's quarterly revenue was down 22.2% compared to the same quarter last year. During the same period last year, the firm posted $0.06 EPS.

What ETFs hold Ardelyx's stock?

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Ardelyx own?
Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.61%), Vanguard Group Inc. (5.60%), Eventide Asset Management LLC (2.93%), Rubric Capital Management LP (1.73%), Price T Rowe Associates Inc. MD (1.00%) and Price T Rowe Associates Inc. MD (1.00%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARDX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners